Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02254772 · ClinicalTrials.gov registry record · Phase 1
A Phase I/II Study of Intratumoral Injection of SD-101
A Phase 1 study, sponsored by Robert Lowsky.
- Completed
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT02254772: Completed Phase 1 study, sponsored by Robert Lowsky.
NCT02254772 is a Phase 1 study that has completed, run by Robert Lowsky. The registered enrollment target is 9 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (85% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02254772, a Phase 1 study, has completed, sponsored by Robert Lowsky.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
This phase 1-2 trial studies the side effects and best dose of ipilimumab in combination with toll-like receptor 9 (TLR9) agonist SD-101 and radiation therapy in treating patients with recurrent low-grade B-cell lymphoma.
Primary Outcome
To determine the safety and tolerability of SD-101 (1 mg/week) and local low dose radiation plus escalating doses of subcutaneously (SC)-administered ipilimumab, the incidence of dose-limiting toxicities (DLT) will be assessed according to the following DLT definitions. Related adverse events (AEs) are toxicities. "Treatment" includes radiation therapy. * Grade 4 treatment-related AE * Any drug-related AE ≥ Grade 3, including injection site reaction * ≥ Grade 3 treatment-related clinical autoim
Interventions
- BIOLOGICAL Ipilimumab
- RADIATION Radiation therapy
- DRUG SD-101
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2014-09 |
| Est. Completion | 2017-01-26 |
| Phase | Phase 1 |
What the finished NCT02254772 record still lists
NCT02254772 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (85% lower).
The record links to 0 conditions, and to 3 interventions - of which Ipilimumab is the first listed.
NCT02254772 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02254772 about?
NCT02254772 is a clinical study titled "A Phase I/II Study of Intratumoral Injection of SD-101". This phase 1-2 trial studies the side effects and best dose of ipilimumab in combination with toll-like receptor 9 (TLR9) agonist SD-101 and radiation therapy in treating patients with recurrent low-grade B-cell lymphoma.
What is the current status of trial NCT02254772?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2014-09. Estimated completion is 2017-01-26.
What interventions are being tested in trial NCT02254772?
The interventions under investigation include: Ipilimumab (BIOLOGICAL), Radiation therapy (RADIATION), SD-101 (DRUG).
Who is sponsoring clinical trial NCT02254772?
This trial is sponsored by Robert Lowsky, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02254772's enrollment target sits among peer trials
9 1955th of 2000 higher than 42 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia